^
Association details:
| Biomarker: | NRAS G13D |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Drug: | ASN007 (ERK2 inhibitor, ERK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
Published date:
07/21/2021
Excerpt:
...ASN007 showed a strong tumor growth inhibition in MINO, a mantle cell lymphoma model with a NRASG13D mutation.
DOI:
10.1016/j.xcrm.2021.100350
